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1. Introduction 
Cyclic peptides are increasingly important and serve as 
relevant lead structures and bioactive molecules in medicinal 
chemistry and drug design since they offer a plethora of 
biological activities and especially interesting for modulation of 
protein-protein interactions.1 Their (total) synthesis, however, is 
still a highly challenging task and the development of novel and 
efficient cyclization approaches is an active field of research.1f 
Within this class, multicyclic as well as side chain knotted cyclic 
peptides, like the conotoxins and cyclotides,2 lantibiotics,3 and 
glycopeptide antibiotics,4 are of special interest since they 
combine extreme potency with shape persistent folding of the 
peptide backbone. The most classical and outstanding example of 
the effects of macrocyclization and side chain knotting is found 
in the heptapeptide vancomycin.5 These lead to an almost 
absolute control of shape and folding of this glycopeptide 
antibiotic and allows for a very strong binding of the rather 
flexible natural target ~Lys-D-Ala-D-Ala-OH.6 
Over the years we have been inspired by cyclized peptides 
such as vancomycin as well as nisin and we have explored 
alternative approaches for peptide cyclization, among others, 
Sonogashira cross-coupling,7 ring closing metathesis8 and Cu+ as 
well as Ru2+ catalyzed azide-alkyne cycloadditions,9 to obtain 
highly constrained side chain to side chain knotted peptides. 
Previously, we have shown that alkyne-, alkene- and triazole-
tethered cyclic tri-, hexa- and heptapeptides could be synthesized 
that mimic vancomycin by binding ~Lys-D-Ala-D-Ala-OH and 
~Lys-D-Ala-D-Lac-OH. To increase the rigidity of these mimics 
further, we were looking for complementary cyclization 
approaches for introducing an additional cyclic constraint to 
control the sequence of cyclization and thereby the folding 
topology of the peptide backbone. So far, most vancomycin 
mimics, including our own, have focused mainly on the CDE-
ring system.10 However, the ABC-ring system probably provides 
the additional needed rigidity in the form of a lid, making 
vancomycin more of a clam to hold ~Lys-D-Ala-D-Ala-OH more 
permanently by reducing the off-rate. Herein, we describe our 
efforts towards effective mimicry of the ABC-ring system,10h, 11, 12 
which ultimately combined with DE-mimicry should lead to 
potent vancomycin mimics. 
 
2. Results and discussion 
Previously we have reported the synthesis of triazole-
containing vancomycin mimics like 14 (Figure 1).9b Despite their 
bicyclic framework these structures are still relatively flexible, 
since mimics as 14 do bind Ac-Lys(Ac)-D-Ala-D-Ala-OH albeit 
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 2 
with a lower affinity than vancomycin as judged by isothermal 
microcalorimetry (ITC). In order to include the AB-ring system,11 
we wished to apply RCM, which we and others have done 
successfully on several occassions.13 This led to the target 
bicyclic tripeptide 10. Retrosynthesis showed that bicycle 10 
might be accessible through two consecutive macrocyclization 
steps starting from 12 (Figure 1). Since the preferred order of the 
macrocyclization steps, by RCM or RuAAC,14 was not known 
(vide infra), precursor dipeptide 7 was proposed, to optimize 
RCM in the presence of an azide moiety (Figure 1). 
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Figure 1. Design of vancomycin mimics. 
 
TMS-protected alkyne 3 was conveniently accessible from 
commercially available 4-hydroxy-D-phenylglycine (Scheme 1). 
After protection of the amine group and conversion of the 
phenolic hydroxy group to a methyl ether and preparation of the 
methyl ester, amino acid derivative 1 was subjected to iodination, 
according to Nicolaou et al.,15 to give mono-iodo compound 2 in 
high yield (90%). After saponification of the methyl ester, the 
alkyne was installed by a Pd-catalyzed Sonogashira cross-
coupling reaction to give protected phenylglycine building block 
3 in an acceptable yield of 57%.16 
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Scheme 1. Synthesis of phenylglycine building block 3. 
 
The synthesis of the required RCM-precursor 7 is shown in 
Scheme 2. To this end 2-allylaniline 4 was obtained by a Claisen 
rearrangement according to Brucelle and Renaud.17 In a first 
attempt to couple aniline 4 to azido acid 5,18 BOP/DIPEA as 
coupling reagent did not afford anilide 6. Therefore, DCC in 
pyridine was used to form the anilide 6 in 54% yield since this 
combination of coupling reagent/solvent was effective in the 
coupling of the poor nucleophile 4-nitroaniline with amino 
acids.19 After deprotection of anilide 6 by treatment with TFA, 
Boc-D-Alg-OH was coupled by BOP/DIPEA, and bisalkene 
dipeptide 7 was obtained in 92% yield over two steps. 
As RCM precursor peptide 7 contained an azide moiety, the 
first20 and second21 generation Grubbs catalysts could not be used 
since the tricyclohexylphosphine ligands would likely reduce the 
azide into an amine via a Staudinger reduction.22 Therefore, the 
second generation Hoveyda-Grubbs catalyst23 was used in 
refluxing CH2Cl2 and macrocyclic peptide 8 was isolated in 55% 
yield as a mixture of the E/Z diastereoisomers, as shown in 
Scheme 3 (8a (Z):8b (E) = 1:2.3). After Boc removal both 
diastereoisomers 8ab could be separated by preparative HPLC 
and characterized as well as identified by NMR and LC-(HR)MS. 
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Scheme 2. Synthesis of RCM precursor dipeptide 7. 
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Scheme 3. RCM–coupling–RuAAC strategy for the synthesis of bicyclic 
tripeptide 10. 
 
In its protected form, both diastereoisomers (Rt 32.97 and 
33.36 min) of macrocycle 8 could not be separated as is shown in 
Figure SI-18. However, when an aliquot of 8 was treated with 
TFA to remove the Boc functionality this resulted in a base line 
separation of both diastereoisomers 8ab (Rt 22.24 and 22.98 min, 
Figure SI-19). The 1H NMR spectrum of diastereoisomer 8a gave 
broad peaks at 25˚C, fortunately at higher temperature, peak 
splitting was observed and at 80˚C a well-defined J coupling of 
the olefinic protons could be derived (Figure SI-11). This value, 
~8 Hz, corresponded to the Z-configuration of the double bond. 
The proton spectrum of diastereoisomer 8b had resulted already 
at 25˚C in a well-defined J coupling of ~13 Hz of the alkene 
bond indicating an E-geometry of 8b (Figure SI-12).24 
Thus, macrocycle 8 was treated with TFA and the free -
amine was coupled to alkyne derivative 3 in the presence of 
BOP/DIPEA to afford the protected click precursor 9 in 54% 
overall yield (Scheme 3). Then, tripeptide 9 was treated with 
TBAF to remove the TMS functionality and the unprotected 
alkyne was isolated in 95% yield after column chromatography 
and subjected to RuAAC in THF/MeOH as solvent system at 
 3 
80˚C under microwave irradiation in the presence of 10 mol% 
[Cp*RuCl]4 as catalyst. Bicyclic tripeptide 10 was isolated in 
22% yield after column chromatography as a mixture of E/Z 
diastereoisomers. Heating at 80˚C under microwave irradiation in 
the absence of [Cp*RuCl]4 did not lead to any conversion. To 
improve the yield of cyclization, lower and higher catalyst 
loadings (5 and 15 mol%, respectively) were used and turned out 
to be ineffective since incomplete conversion of starting material 
(at 5 mol%) or extensive formation of baseline compounds (at 15 
mol%) were observed instead. As a control experiment, the 
unprotected alkyne was also subjected to regular CuAAC25 in the 
presence of either CuI or [Cu(CH3CN)4]PF6 as the Cu
+ species, 
and these reaction conditions did not lead to the formation of 
bicyclic tripeptide 10. This experiment showed that a 1,5-triazole 
moiety with a curved geometry was essential for ring closure 
since the more linear geometry of the 1,4-triazole was clearly 
incompatible with the topology of the bicyclic framework of 
tripeptide 10. Similar to macrocycle 8, the individual 
diastereoisomers of bicylic tripeptide 11 (Z-11a and E-11b, 
respectively) could be obtained after Boc removal of 10 and 
purification by preparative HPLC. It is interesting to note that the 
Z:E ratio during the conversion of 8ab into 11ab shifted from 
1:2.3 to 2:1, an indication that the Z-geometry of the alkene was 
favored in the bicyclic tripeptide topology. 
Since bicyclic tripeptide 11 can be used as a versatile building 
block in the synthesis of tricyclic heptapeptides to mimic the side 
chain to side chain connectivity pattern of vancomycin, 
hydrogenation of the double bond to an alkane bridge would be 
desirable to obtain a single isomer instead of an E/Z mixture of 
diastereoisomers. Therefore, several hydrogenation conditions in 
the presence of Pd/C, Raney Ni, and Pd(OH)2 were investigated, 
unfortunately all were unsuccessful. 
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Scheme 4. Alternative RCM–coupling–RuAAC strategies for the 
synthesis of bicyclic tripeptide 10. 
 
Two reverse reaction sequences to arrive at the desired 
bicyclic tripeptide 10 were also investigated, both started from 
linear dipeptide 7 (Scheme 4). As the first step, Boc-protected 7 
was treated with TFA and the resulting amine was coupled to 
alkyne derivative 3 in the presence of BOP/DIPEA to afford 
tripeptide 12 in 69% yield after purification by column 
chromatography. RCM of precursor peptide 12 in the presence of 
Hoveyda-Grubbs 2G catalyst in CH2Cl2 or 1,2-dichloroethane did 
not result in the formation of alkene-bridged macrocycle 9. The 
progress of the reaction was monitored by LCMS, although 
starting material was gone, the desired bicyclic peptide 9 could 
not be observed. In hindsight, it was assumed that the desired 
ene-ene RCM pathway was possibly overrun by the 
thermodynamically favored ene-yne reactivity to yield 2-silyl-
substituted 1,3-dienes, which were not identified.26 
Alternatively, TMS-protected precursor peptide 12 was treated 
with TBAF and subsequently subjected to RuAAC to install the 
triazole moiety as the cyclic constraint. Via this route, 
macrocycle 13 was obtained in a better 41% yield than in the 
above preparation of 10 (Scheme 3). Unfortunately, RCM of 13 
did not result in the successful isolation of bicyclic tripeptide 10. 
TLC analysis indicated that conversion of the starting compound 
was not complete and some baseline material was present and the 
formation of bicyclic tripeptide 10 could not be observed by 
LCMS. 
 
Figure 2. Superimposition of balhimycin (in red) with bicyclic tripeptide 
11a (left) and 11b (right), respectively. The carbon atoms C1, C2, C3, 
arom-C4, triazole-C5, N6, benzylic-C7 have been used as fixed coordinates for 
superimposition. 
 
Table 1. The binding affinity as measured using ITC. 
compound ligand Ka (M-1)a 
VM Ac-Lys(Ac)-D-Ala-D-Ala-OH (3.95±0.41)×105 
VM Ac-Lys(Ac)-D-Ala-D-Lac-OH (2.38±0.23)×103 
11a Ac-Lys(Ac)-D-Ala-D-Ala-OH (2.35±0.36)×103 
11a Ac-Lys(Ac)-D-Ala-D-Lac-OH (2.17±0.30)×103 
11b Ac-Lys(Ac)-D-Ala-D-Ala-OH (4.06±0.84)×103 
11b Ac-Lys(Ac)-D-Ala-D-Lac-OH (1.21±0.86)×103 
aMeasured in a Na-citrate/citric acid buffer (0.02 M, pH 5.1), VM: 
vancomycin. 
 
The structures of bicyclic tripeptides 11a (as the Z-
diastereoisomer) and 11b (as the E- diastereoisomer) were energy 
minimized using the simulated annealing protocol employing the 
AMBER99 force field using the YASARA Structure 10.5.2.1 
software package.27 The peptides were superimposed with the left 
half of the vancomycin-related balhimycin antibiotic comprising 
the ABC-ring system.28 An RMSD of 0.76 and 0.58 Å over seven 
atoms was calculated (see Scheme 3 for atom numbering) of the 
superimpositions of 11a and 11b, respectively. To evaluate if this 
structural resemblance correlates with binding affinity toward 
Ac-Lys(Ac)-D-Ala-D-Ala-OH and Ac-Lys(Ac)-D-Ala-D-Lac-OH, 
isothermal microcalorimetry (ITC) was performed, as shown in 
Table 1.29, 30 Based on these data, mimics 11a and 11b still bind 
Ac-Lys(Ac)-D-Ala-D-Ala-OH appreciably, considering that a 
large part of the 'clam' is missing, albeit at least 100-fold less 
compared to vancomycin. Bicycle 11b is somewhat more active 
than 11a, while binding toward Ac-Lys(Ac)-D-Ala-D-Lac-OH 
was comparable for all three receptor molecules. This was in line 
with the MIC-values obtained from a growth inhibition assay31 of 
Staphylococcus aureus ATCC 49320 strain, since 300 g/mL 
(11b), >300 g/mL (11a) and 2 g/mL (VM) were found, 
respectively. Although a reasonable structural resemblance was 
found, not unexpectedly, for efficient binding (and activity) some 
extra factors need to be addressed like proper alignment of 
 4 
hydrogen bonding and further rigidification, possibly in 
attempts to combine the ABC and CDE-ring systems.9b 
 
3. Conclusion 
In conclusion, bicyclic tripeptide 10 as a mimic of the ABC-
ring system was successfully synthesized starting from precursor 
dipeptide 7 following an RCM-coupling-RuAAC strategy. 
Mimics of this part of the vancomycin structure are less explored 
as only a single hydrogen bond contributes to the binding of Ac-
Lys(Ac)-D-Ala-D-Ala-OH via the carbonyl oxygen of the lysine 
residue. The mixture of double bond isomers could be separated 
in each individual E/Z diastereoisomer as the free amine by 
HPLC as judged by NMR and LC-MS. Bicyclic tripeptide 10 is 
an important building block to ultimately arrive at a series of 
tricyclic heptapeptides for possible effective mimicry of 
vancomycin in which ruthenium-based cyclization approaches 
will be used to control the topology and rigidity of the peptide 
backbone. 
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